PXB-cells® and PXB-mouse® against viral Hepatitis

PhoenixBio is attending HEP DART 2019 in beautiful Kauai, Hawaii on December 8-12, 2019.

HEP DART 2019 uniquely blends the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community with an increased understanding of the current and future challenges in hepatology (including viral hepatitis, NASH, and co-infections). The program includes plenary lectures, abstract and poster presentations, along with discussion & debate.

In anticipation of the meeting, we would like to share Hepatitis-related studies with PXB-cells® and PXB-mouse®

Hepatitis B studies in PXB-cells®

Anti-HBV activity evaluation of Interferon-like small molecule: 35 days study (28 days of culturing post-infection + 7 days of treatment) utilizing 96- and 24-well plates.
Furutani Y. et al. PLoS ONE2019; 14(6): e0216139

Small molecule viral expression inhibitor study: PXB-cells® were used to directly test the impact of PAPD5 and PAPD7 mRNA knockdown on individual HBV RNA types.
Mueller H. et al. Hepatology 2019; 69(4): 1398-1411

Gene silencing technology for HBV application: 12 days to establish HBV infection and 16 days after transducing infected cells with shRNA vector or control.
Suhy D. Poster presentation at ESGCT Congress 2016 

HBV_Hepatitis_B studies in PXBmouse and PXBcells

Hepatitis B studies in PXB-mouse®

Capsid assembly modulator designed to block the production of HBV replication products: Two separate in vivo studies were performed with a total of 61 mice. Efficacy of monotherapies and combinations with entecavir and Peg-IFN were studies.
Klumpp K. et al. Gastroenterology 2018; 154: 652-662

Small molecule HBV viral gene expression inhibitor study: The selectivity of compound for HBV was confirmed in vivo using PXB-mouse®. Combination therapy with entecavir and/or PEG-IFN-alpha improved anti-viral profile and potency.
Mueller H. et al. Hepatology 2019; 69(4): 1398-1411

DNA-directed RNA interference agent: the transduced, HBV infected mice were followed for 56 days. Weekly monitoring of extracellular HBV DNA, hAlb, HBsAg and HBeAg. Terminal assays: intracellular HBV DNA, ccc DNA, HBV viral transcripts, production of anti-HBV shRNA.
Suhy D. Poster presentation at ESGCT Congress 2016  

Hepatitis B and Hepatitis D: coinfection and superinfection model

Anti-HBV and anti-HDV effects of compounds in hemizygous cDNA-uPA/SCID chimeric mouse (PXB-mouse®) with HBV/HDV dual chronic infection were evaluated. One compound (siRNA agent designed to cleave HBV RNAs) reduced both HBV and HDV viremia, while anti-HDV siRNA only inhibited HDV and PEG-IFN-alpha only inhibited HBV.
Ye X. et al. ACS Infect Dis 2018; 5: 738-749

Hepatitis B and Hepatitis D (HBV & HDV) coinfection in PXBmouse and PXBcells

Please feel free to contact us to learn more about the PXB-Mouse®, the most widely used chimeric mouse with humanized liver, and PXB-cells®, fresh human hepatocytes isolated from PXB-Mouse®. 

Hepatitis B: Key Facts

  • WHO estimates that in 2015, 257 million people were living with chronic hepatitis B infection
  • In 2015, hepatitis B resulted in an estimated 887 000 deaths
  • As of 2016, 27 million people (10.5% of all people estimated to be living with hepatitis B) were aware of their infection, while 4.5 million (16.7%) of the people diagnosed were on treatment

Source: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b